K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This early-stage trial tested a new drug called azenosertib (ZN-c3) combined with the chemotherapy gemcitabine in 31 people aged 12 and older with osteosarcoma that had relapsed or stopped responding to treatment. The goal was to see if the combination is safe and whether it can …

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…